Quotes 5-day view Delayed Nasdaq
05/16/2022
05/17/2022
05/18/2022
05/19/2022
05/20/2022
Date
0.4465(c)
0.4829(c)
0.4621(c)
0.4749(c)
0.4444(c)
Last
640 076
520 294
180 342
105 930
225 270
Volume
+4.32%
+8.15%
-4.31%
+2.77%
-6.42%
Change
Estimated financial data (e) (USD)
Sales 2022
25,0 M
-
-
Net income 2022
-76,1 M
-
-
Net Debt 2022
-
-
-
P/E ratio 2022
-0,40x
Yield 2022
-
Sales 2023
31,5 M
-
-
Net income 2023
-73,2 M
-
-
Net Debt 2023
-
-
-
P/E ratio 2023
-0,48x
Yield 2023
-
Capitalization
30,7 M
30,7 M
-
Capi. / Sales 2022
1,23x
Capi. / Sales 2023
0,98x
Nbr of Employees
89
Free-Float
88,2%
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of a echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and...
Ratings of Cidara Therapeutics, Inc.
All news about CIDARA THERAPEUTICS, INC.
News in other languages on CIDARA THERAPEUTICS, INC.
Analyst Recommendations on CIDARA THERAPEUTICS, INC.
Chart CIDARA THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CIDARA THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0,44 $
Average target price
5,67 $
Spread / Average Target
1 175%
Please enable JavaScript in your browser's settings to use dynamic charts.